HC Wainwright Decreases Earnings Estimates for Cytosorbents

Cytosorbents Corporation (NASDAQ:CTSO) – Investment analysts at HC Wainwright decreased their Q3 2026 EPS estimates for shares of Cytosorbents in a report issued on Friday, August 7th. HC Wainwright analyst S. Lee now anticipates that the medical research company will earn ($0.04) per share for the quarter, down from their previous forecast of ($0.03). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Cytosorbents’ Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.22) EPS, FY2027 earnings at $0.00 EPS, FY2028 earnings at $0.03 EPS and FY2029 earnings at $0.04 EPS.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.03). Cytosorbents had a negative return on equity of 309.53% and a negative net margin of 48.94%.The company had revenue of $9.63 million during the quarter, compared to analyst estimates of $9.38 million.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cytosorbents in a research note on Monday, July 6th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $5.38.

Cytosorbents Stock Performance

NASDAQ:CTSO opened at $0.36 on Tuesday. The company has a market cap of $22.75 million, a P/E ratio of -1.25 and a beta of 1.39. The firm’s 50 day moving average is $0.40 and its two-hundred day moving average is $0.55. Cytosorbents has a fifty-two week low of $0.35 and a fifty-two week high of $1.22. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 4.70.

Hedge Funds Weigh In On Cytosorbents

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. grew its stake in shares of Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after acquiring an additional 37,519 shares in the last quarter. Citadel Advisors LLC lifted its stake in shares of Cytosorbents by 127.3% in the third quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after acquiring an additional 36,790 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new position in shares of Cytosorbents in the third quarter worth about $161,000. CM Management LLC lifted its stake in shares of Cytosorbents by 14.6% in the fourth quarter. CM Management LLC now owns 1,476,500 shares of the medical research company’s stock worth $944,000 after acquiring an additional 188,372 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Cytosorbents by 3.7% in the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after purchasing an additional 79,535 shares during the last quarter. 32.87% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Phillip P. Chan purchased 251,136 shares of the stock in a transaction that occurred on Friday, June 12th. The stock was acquired at an average cost of $0.40 per share, with a total value of $100,454.40. Following the acquisition, the chief executive officer owned 1,734,099 shares in the company, valued at approximately $693,639.60. This trade represents a 16.93% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 7.80% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.